LS CancerDiag‘s ultimate mission is to reduce cancer mortality rates, a mission that’s underpinned by a vision for DiagMMR to become the new global standard test for Lynch syndrome diagnosis. DiagMMR is a simple and accurate diagnostic method for inherited MMR deficiency, which is linked to Lynch syndrome, the most prevalent inherited cancer predisposition worldwide.
Current Lynch syndrome diagnosis relies heavily on tumor studies and DNA sequencing, but limitations in these methods led LS CancerDiag‘s founder to seek a new way. DiagMMR is the result of many years of dedicated research, an innovation that dramatically simplifies the diagnostics of Lynch syndrome to enable preventive care and help save lives.
CIO INFLUENCE: CIO Influence Interview with Russ Ernst, Chief Technology Officer at Blancco
LS CancerDiag‘s important work started in the labs of the University of Helsinki and has been clinically validated and launched in local markets. Now, the company is entering a new stage of growth: bringing this breakthrough test to the United States.
“We are excited about our new partnership with Altitude Marketing. As we are increasing our efforts to introduce our diagnostic solutions to the US market, having an appealing and consistent brand strategy and reliable marketing execution is critical,” said Philippe Arnez, Chief Business Officer of LS CancerDiag. “The partnership allows us to step up our game by bringing in a marketing professional based in the US as an extension of our own team, which is based in Finland. This will be of great help, and with their integrated services and B2B specialization, we are confident that together we can bring our company to life and establish a strong brand presence in this important market.”
CIO INFLUENCE: CIO Influence Interview with Bill Lobig, VP of Product Management at IBM Automation
Together, Altitude and LS CancerDiag will embark on a rebranding project to elevate the company’s visual and verbal identity. This includes developing a new name, crafting new messaging, enhancing their web presence – and reinforcing their position as the global leader for Lynch syndrome diagnostics that they are.
“We absolutely love working with companies that are going to change the world for the better,” said Andrew Stanten, CEO of Altitude Marketing. “With an estimated 1 in 300 people affected by Lynch syndrome, millions of people have a highly increased risk for certain hereditary cancers. LS CancerDiag is going to change that with its early detection assay. We are honored to have been selected as the company’s branding and marketing partner moving forward.”
CIO INFLUENCE: CIO Influence Interview with Antoine Jebara, Co-Founder and GM, MSP Products at JumpCloud
[To share your insights with us, please write to sghosh@martechseries.com]
